City of Hope has evaluated Curate Biosciences’ Cell Processing System for advanced cell separation and plans to integrate the platform into its workflow to manufacture investigational CAR T-cell immunotherapy, the company said.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
